Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

OBJECTIVE: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC. METHODS: The SENSCIS trial enrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Maher, Toby M, Volkmann, Elizabeth R, Allanore, Yannick, Smith, Vanessa, Assassi, Shervin, Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Kuwana, Masataka, Stock, Christian, Alves, Margarida, Sambevski, Steven, Denton, Christopher P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936273/
https://www.ncbi.nlm.nih.gov/pubmed/36796874
http://dx.doi.org/10.1136/rmdopen-2022-002859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936273/
https://www.ncbi.nlm.nih.gov/pubmed/36796874
http://dx.doi.org/10.1136/rmdopen-2022-002859

Ejemplares similares